0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Multiple Sclerosis Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
Published Date: December 2022
|
Report Code: QYRE-Auto-12O297
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Multiple Sclerosis Therapeutics Market Insights Forecast to 2028
BUY CHAPTERS

Global Multiple Sclerosis Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Code: QYRE-Auto-12O297
Report
December 2022
Pages:95
QYResearch
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause the nerves themselves to deteriorate or become permanently damaged.
Report Overview

Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Multiple Sclerosis Therapeutics estimated at US$ 17400 million in the year 2022, is projected to reach a revised size of US$ 19600 million by 2028, growing at a CAGR of 2.0% during the forecast period 2022-2028.

The USA market for Multiple Sclerosis Therapeutics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The China market for Multiple Sclerosis Therapeutics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The Europe market for Multiple Sclerosis Therapeutics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The global key companies of Multiple Sclerosis Therapeutics include Novartis, Teva Pharmaceuticals, Sanofi Genzyme, Bayer, Pfizer, Biogen Idec, Merck and AbbVie, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Multiple Sclerosis Therapeutics companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Multiple Sclerosis Therapeutics market. Further, it explains the major drivers and regional dynamics of the global Multiple Sclerosis Therapeutics market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Novartis
Teva Pharmaceuticals
Sanofi Genzyme
Bayer
Pfizer
Biogen Idec
Merck
AbbVie
Market Segments
This report has explored the key segments: by Type and by Distribution Channel. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by distribution channel segments based on value for the period 2017-2028.

Multiple Sclerosis Therapeutics Segment by Type

Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others
Multiple Sclerosis Therapeutics Segment by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
e-Commerce
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Multiple Sclerosis Therapeutics market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Multiple Sclerosis Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Multiple Sclerosis Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Multiple Sclerosis Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Multiple Sclerosis Therapeutics revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Multiple Sclerosis Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Multiple Sclerosis Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Novartis, Teva Pharmaceuticals, Sanofi Genzyme, Bayer, Pfizer, Biogen Idec, Merck and AbbVie, etc.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Multiple Sclerosis Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Beta Interferon
1.2.3 Corticosteroids
1.2.4 Monoclonal Antibodies
1.2.5 Antineoplastic Agents
1.2.6 Others
1.3 Market by Distribution Channel
1.3.1 Global Multiple Sclerosis Therapeutics Market Growth Rate by Distribution Channel: 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 e-Commerce
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Multiple Sclerosis Therapeutics Market Size (2017-2028)
2.2 Multiple Sclerosis Therapeutics Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.3 Global Multiple Sclerosis Therapeutics Market Size by Region (2017-2022)
2.4 Global Multiple Sclerosis Therapeutics Market Size Forecast by Region (2023-2028)
2.5 Global Top Multiple Sclerosis Therapeutics Countries Ranking by Market Size
3 Multiple Sclerosis Therapeutics Competitive by Company
3.1 Global Multiple Sclerosis Therapeutics Revenue by Players
3.1.1 Global Multiple Sclerosis Therapeutics Revenue by Players (2017-2022)
3.1.2 Global Multiple Sclerosis Therapeutics Market Share by Players (2017-2022)
3.2 Global Multiple Sclerosis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Multiple Sclerosis Therapeutics Revenue
3.4 Global Multiple Sclerosis Therapeutics Market Concentration Ratio
3.4.1 Global Multiple Sclerosis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Multiple Sclerosis Therapeutics Revenue in 2021
3.5 Global Multiple Sclerosis Therapeutics Key Players Head office and Area Served
3.6 Key Players Multiple Sclerosis Therapeutics Product Solution and Service
3.7 Date of Enter into Multiple Sclerosis Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Multiple Sclerosis Therapeutics Breakdown Data by Type
4.1 Global Multiple Sclerosis Therapeutics Historic Revenue by Type (2017-2022)
4.2 Global Multiple Sclerosis Therapeutics Forecasted Revenue by Type (2023-2028)
5 Global Multiple Sclerosis Therapeutics Breakdown Data by Distribution Channel
5.1 Global Multiple Sclerosis Therapeutics Historic Market Size by Distribution Channel (2017-2022)
5.2 Global Multiple Sclerosis Therapeutics Forecasted Market Size by Distribution Channel (2023-2028)
6 North America
6.1 North America Multiple Sclerosis Therapeutics Revenue by Company (2020-2022)
6.2 North America Multiple Sclerosis Therapeutics Revenue by Type (2017-2028)
6.3 North America Multiple Sclerosis Therapeutics Revenue by Distribution Channel (2017-2028)
6.4 North America Multiple Sclerosis Therapeutics Revenue by Country (2017-2028)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Multiple Sclerosis Therapeutics Revenue by Company (2020-2022)
7.2 Europe Multiple Sclerosis Therapeutics Revenue by Type (2017-2028)
7.3 Europe Multiple Sclerosis Therapeutics Revenue by Distribution Channel (2017-2028)
7.4 Europe Multiple Sclerosis Therapeutics Revenue by Country (2017-2028)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Multiple Sclerosis Therapeutics Revenue by Company (2020-2022)
8.2 Asia Pacific Multiple Sclerosis Therapeutics Revenue by Type (2017-2028)
8.3 Asia Pacific Multiple Sclerosis Therapeutics Revenue by Distribution Channel (2017-2028)
8.4 Asia Pacific Multiple Sclerosis Therapeutics Revenue by Region (2017-2028)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Multiple Sclerosis Therapeutics Revenue by Company (2020-2022)
9.2 Latin America Multiple Sclerosis Therapeutics Revenue by Type (2017-2028)
9.3 Latin America Multiple Sclerosis Therapeutics Revenue by Distribution Channel (2017-2028)
9.4 Latin America Multiple Sclerosis Therapeutics Revenue by Country (2017-2028)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Multiple Sclerosis Therapeutics Revenue by Company (2020-2022)
10.2 Middle East and Africa Multiple Sclerosis Therapeutics Revenue by Type (2017-2028)
10.3 Middle East and Africa Multiple Sclerosis Therapeutics Revenue by Distribution Channel (2017-2028)
10.4 Middle East and Africa Multiple Sclerosis Therapeutics Revenue by Country (2017-2028)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Multiple Sclerosis Therapeutics Products and Services
11.1.4 Novartis Multiple Sclerosis Therapeutics Revenue in Multiple Sclerosis Therapeutics Business (2017-2022)
11.1.5 Novartis Multiple Sclerosis Therapeutics SWOT Analysis
11.1.6 Novartis Recent Developments
11.2 Teva Pharmaceuticals
11.2.1 Teva Pharmaceuticals Company Details
11.2.2 Teva Pharmaceuticals Business Overview
11.2.3 Teva Pharmaceuticals Multiple Sclerosis Therapeutics Products and Services
11.2.4 Teva Pharmaceuticals Multiple Sclerosis Therapeutics Revenue in Multiple Sclerosis Therapeutics Business (2017-2022)
11.2.5 Teva Pharmaceuticals Multiple Sclerosis Therapeutics SWOT Analysis
11.2.6 Teva Pharmaceuticals Recent Developments
11.3 Sanofi Genzyme
11.3.1 Sanofi Genzyme Company Details
11.3.2 Sanofi Genzyme Business Overview
11.3.3 Sanofi Genzyme Multiple Sclerosis Therapeutics Products and Services
11.3.4 Sanofi Genzyme Multiple Sclerosis Therapeutics Revenue in Multiple Sclerosis Therapeutics Business (2017-2022)
11.3.5 Sanofi Genzyme Multiple Sclerosis Therapeutics SWOT Analysis
11.3.6 Sanofi Genzyme Recent Developments
11.4 Bayer
11.4.1 Bayer Company Details
11.4.2 Bayer Business Overview
11.4.3 Bayer Multiple Sclerosis Therapeutics Products and Services
11.4.4 Bayer Multiple Sclerosis Therapeutics Revenue in Multiple Sclerosis Therapeutics Business (2017-2022)
11.4.5 Bayer Multiple Sclerosis Therapeutics SWOT Analysis
11.4.6 Bayer Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Multiple Sclerosis Therapeutics Products and Services
11.5.4 Pfizer Multiple Sclerosis Therapeutics Revenue in Multiple Sclerosis Therapeutics Business (2017-2022)
11.5.5 Pfizer Multiple Sclerosis Therapeutics SWOT Analysis
11.5.6 Pfizer Recent Developments
11.6 Biogen Idec
11.6.1 Biogen Idec Company Details
11.6.2 Biogen Idec Business Overview
11.6.3 Biogen Idec Multiple Sclerosis Therapeutics Products and Services
11.6.4 Biogen Idec Multiple Sclerosis Therapeutics Revenue in Multiple Sclerosis Therapeutics Business (2017-2022)
11.6.5 Biogen Idec Multiple Sclerosis Therapeutics SWOT Analysis
11.6.6 Biogen Idec Recent Developments
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Multiple Sclerosis Therapeutics Products and Services
11.7.4 Merck Multiple Sclerosis Therapeutics Revenue in Multiple Sclerosis Therapeutics Business (2017-2022)
11.7.5 Merck Multiple Sclerosis Therapeutics SWOT Analysis
11.7.6 Merck Recent Developments
11.8 AbbVie
11.8.1 AbbVie Company Details
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Multiple Sclerosis Therapeutics Products and Services
11.8.4 AbbVie Multiple Sclerosis Therapeutics Revenue in Multiple Sclerosis Therapeutics Business (2017-2022)
11.8.5 AbbVie Multiple Sclerosis Therapeutics SWOT Analysis
11.8.6 AbbVie Recent Developments
12 Multiple Sclerosis Therapeutics Market Dynamics
12.1 Multiple Sclerosis Therapeutics Market Trends
12.2 Multiple Sclerosis Therapeutics Market Drivers
12.3 Multiple Sclerosis Therapeutics Market Challenges
12.4 Multiple Sclerosis Therapeutics Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
List of Tables
    Table 1. Global Multiple Sclerosis Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Beta Interferon
    Table 3. Key Players of Corticosteroids
    Table 4. Key Players of Monoclonal Antibodies
    Table 5. Key Players of Antineoplastic Agents
    Table 6. Key Players of Others
    Table 7. Global Multiple Sclerosis Therapeutics Market Size Growth Rate by Distribution Channel (US$ Million), 2017 VS 2021 VS 2028
    Table 8. Global Multiple Sclerosis Therapeutics Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
    Table 9. Global Multiple Sclerosis Therapeutics Revenue by Region (2017-2022) & (US$ Million)
    Table 10. Global Multiple Sclerosis Therapeutics Revenue Market Share by Region (2017-2022)
    Table 11. Global Multiple Sclerosis Therapeutics Revenue by Players (2017-2022) & (US$ Million)
    Table 12. Global Multiple Sclerosis Therapeutics Market Share by Players (2017-2022)
    Table 13. Global Top Multiple Sclerosis Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Sclerosis Therapeutics as of 2021)
    Table 14. Ranking of Global Top Multiple Sclerosis Therapeutics Companies by Revenue (US$ Million) in 2021
    Table 15. Global 5 Largest Players Market Share by Multiple Sclerosis Therapeutics Revenue (CR5 and HHI) & (2017-2022)
    Table 16. Key Players Headquarters and Area Served
    Table 17. Key Players Multiple Sclerosis Therapeutics Product Solution and Service
    Table 18. Date of Key Manufacturers Enter into Multiple Sclerosis Therapeutics Market
    Table 19. Mergers & Acquisitions, Expansion Plans
    Table 20. Global Multiple Sclerosis Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 21. Global Multiple Sclerosis Therapeutics Revenue Market Share by Type (2017-2022)
    Table 22. Global Multiple Sclerosis Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 23. Global Multiple Sclerosis Therapeutics Revenue Market Share by Type (2023-2028)
    Table 24. Global Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2017-2022) & (US$ Million)
    Table 25. Global Multiple Sclerosis Therapeutics Revenue Market Share by Distribution Channel (2017-2022)
    Table 26. Global Multiple Sclerosis Therapeutics Forecasted Market Size by Distribution Channel (2023-2028) & (US$ Million)
    Table 27. Global Multiple Sclerosis Therapeutics Revenue Market Share by Distribution Channel (2023-2028)
    Table 28. North America Multiple Sclerosis Therapeutics Revenue by Company (2020-2022) & (US$ Million)
    Table 29. North America Multiple Sclerosis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 30. North America Multiple Sclerosis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 31. North America Multiple Sclerosis Therapeutics Revenue by Distribution Channel (2017-2022) & (US$ Million)
    Table 32. North America Multiple Sclerosis Therapeutics Revenue by Distribution Channel (2023-2028) & (US$ Million)
    Table 33. North America Multiple Sclerosis Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 34. North America Multiple Sclerosis Therapeutics Revenue by Country (2023-2028) & (US$ Million)
    Table 35. Europe Multiple Sclerosis Therapeutics Revenue by Company (2020-2022) & (US$ Million)
    Table 36. Europe Multiple Sclerosis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 37. Europe Multiple Sclerosis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 38. Europe Multiple Sclerosis Therapeutics Revenue by Distribution Channel (2017-2022) & (US$ Million)
    Table 39. Europe Multiple Sclerosis Therapeutics Revenue by Distribution Channel (2023-2028) & (US$ Million)
    Table 40. Europe Multiple Sclerosis Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 41. Europe Multiple Sclerosis Therapeutics Revenue by Country (2023-2028) & (US$ Million)
    Table 42. Asia Pacific Multiple Sclerosis Therapeutics Revenue by Company (2020-2022) & (US$ Million)
    Table 43. Asia Pacific Multiple Sclerosis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 44. Asia Pacific Multiple Sclerosis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 45. Asia Pacific Multiple Sclerosis Therapeutics Revenue by Distribution Channel (2017-2022) & (US$ Million)
    Table 46. Asia Pacific Multiple Sclerosis Therapeutics Revenue by Distribution Channel (2023-2028) & (US$ Million)
    Table 47. Asia Pacific Multiple Sclerosis Therapeutics Revenue by Region (2017-2022) & (US$ Million)
    Table 48. Asia Pacific Multiple Sclerosis Therapeutics Revenue by Region (2023-2028) & (US$ Million)
    Table 49. Latin America Multiple Sclerosis Therapeutics Revenue by Company (2020-2022) & (US$ Million)
    Table 50. Latin America Multiple Sclerosis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 51. Latin America Multiple Sclerosis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 52. Latin America Multiple Sclerosis Therapeutics Revenue by Distribution Channel (2017-2022) & (US$ Million)
    Table 53. Latin America Multiple Sclerosis Therapeutics Revenue by Distribution Channel (2023-2028) & (US$ Million)
    Table 54. Latin America Multiple Sclerosis Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 55. Latin America Multiple Sclerosis Therapeutics Revenue by Country (2023-2028) & (US$ Million)
    Table 56. Middle East and Africa Multiple Sclerosis Therapeutics Revenue by Company (2020-2022) & (US$ Million)
    Table 57. Middle East and Africa Multiple Sclerosis Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 58. Middle East and Africa Multiple Sclerosis Therapeutics Revenue by Type (2023-2028) & (US$ Million)
    Table 59. Middle East and Africa Multiple Sclerosis Therapeutics Revenue by Distribution Channel (2017-2022) & (US$ Million)
    Table 60. Middle East and Africa Multiple Sclerosis Therapeutics Revenue by Distribution Channel (2023-2028) & (US$ Million)
    Table 61. Middle East and Africa Multiple Sclerosis Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 62. Middle East and Africa Multiple Sclerosis Therapeutics Revenue by Country (2023-2028) & (US$ Million)
    Table 63. Novartis Company Details
    Table 64. Novartis Business Overview
    Table 65. Novartis Multiple Sclerosis Therapeutics Product and Services
    Table 66. Novartis Multiple Sclerosis Therapeutics Revenue in Multiple Sclerosis Therapeutics Business (2017-2022) & (US$ Million)
    Table 67. Novartis Multiple Sclerosis Therapeutics SWOT Analysis
    Table 68. Novartis Recent Developments
    Table 69. Teva Pharmaceuticals Company Details
    Table 70. Teva Pharmaceuticals Business Overview
    Table 71. Teva Pharmaceuticals Multiple Sclerosis Therapeutics Product and Services
    Table 72. Teva Pharmaceuticals Multiple Sclerosis Therapeutics Revenue in Multiple Sclerosis Therapeutics Business (2017-2022) & (US$ Million)
    Table 73. Teva Pharmaceuticals Multiple Sclerosis Therapeutics SWOT Analysis
    Table 74. Teva Pharmaceuticals Recent Developments
    Table 75. Sanofi Genzyme Company Details
    Table 76. Sanofi Genzyme Business Overview
    Table 77. Sanofi Genzyme Multiple Sclerosis Therapeutics Product and Services
    Table 78. Sanofi Genzyme Multiple Sclerosis Therapeutics Revenue in Multiple Sclerosis Therapeutics Business (2017-2022) & (US$ Million)
    Table 79. Sanofi Genzyme Multiple Sclerosis Therapeutics SWOT Analysis
    Table 80. Sanofi Genzyme Recent Developments
    Table 81. Bayer Company Details
    Table 82. Bayer Business Overview
    Table 83. Bayer Multiple Sclerosis Therapeutics Product and Services
    Table 84. Bayer Multiple Sclerosis Therapeutics Revenue in Multiple Sclerosis Therapeutics Business (2017-2022) & (US$ Million)
    Table 85. Bayer Multiple Sclerosis Therapeutics SWOT Analysis
    Table 86. Bayer Recent Developments
    Table 87. Pfizer Company Details
    Table 88. Pfizer Business Overview
    Table 89. Pfizer Multiple Sclerosis Therapeutics Product and Services
    Table 90. Pfizer Multiple Sclerosis Therapeutics Revenue in Multiple Sclerosis Therapeutics Business (2017-2022) & (US$ Million)
    Table 91. Pfizer Multiple Sclerosis Therapeutics SWOT Analysis
    Table 92. Pfizer Recent Developments
    Table 93. Biogen Idec Company Details
    Table 94. Biogen Idec Business Overview
    Table 95. Biogen Idec Multiple Sclerosis Therapeutics Product and Services
    Table 96. Biogen Idec Multiple Sclerosis Therapeutics Revenue in Multiple Sclerosis Therapeutics Business (2017-2022) & (US$ Million)
    Table 97. Biogen Idec Multiple Sclerosis Therapeutics SWOT Analysis
    Table 98. Biogen Idec Recent Developments
    Table 99. Merck Company Details
    Table 100. Merck Business Overview
    Table 101. Merck Multiple Sclerosis Therapeutics Product and Services
    Table 102. Merck Multiple Sclerosis Therapeutics Revenue in Multiple Sclerosis Therapeutics Business (2017-2022) & (US$ Million)
    Table 103. Merck Multiple Sclerosis Therapeutics SWOT Analysis
    Table 104. Merck Recent Developments
    Table 105. AbbVie Company Details
    Table 106. AbbVie Business Overview
    Table 107. AbbVie Multiple Sclerosis Therapeutics Product and Services
    Table 108. AbbVie Multiple Sclerosis Therapeutics Revenue in Multiple Sclerosis Therapeutics Business (2017-2022) & (US$ Million)
    Table 109. AbbVie Multiple Sclerosis Therapeutics SWOT Analysis
    Table 110. AbbVie Recent Developments
    Table 111. Multiple Sclerosis Therapeutics Market Trends
    Table 112. Multiple Sclerosis Therapeutics Market Drivers
    Table 113. Multiple Sclerosis Therapeutics Market Challenges
    Table 114. Multiple Sclerosis Therapeutics Market Restraints
    Table 115. Research Programs/Design for This Report
    Table 116. Key Data Information from Secondary Sources
    Table 117. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Multiple Sclerosis Therapeutics Sales Market Share by Type: 2021 VS 2028
    Figure 2. Beta Interferon Features
    Figure 3. Corticosteroids Features
    Figure 4. Monoclonal Antibodies Features
    Figure 5. Antineoplastic Agents Features
    Figure 6. Others Features
    Figure 7. Global Multiple Sclerosis Therapeutics Sales Market Share by Distribution Channel: 2021 VS 2028
    Figure 8. Hospital Pharmacies Case Studies
    Figure 9. Retail Pharmacies Case Studies
    Figure 10. e-Commerce Case Studies
    Figure 11. Multiple Sclerosis Therapeutics Report Years Considered
    Figure 12. Global Multiple Sclerosis Therapeutics Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 13. Global Multiple Sclerosis Therapeutics Market Size 2017-2028 (US$ Million)
    Figure 14. Global Multiple Sclerosis Therapeutics Market Size Market Share by Region: 2021 VS 2028
    Figure 15. Global Multiple Sclerosis Therapeutics Revenue Market Share by Region in 2017 VS 2022
    Figure 16. Global Top 10 Multiple Sclerosis Therapeutics Countries Ranking by Market Size (US$ Million) in 2021
    Figure 17. Global Multiple Sclerosis Therapeutics Market Share by Players in 2021
    Figure 18. Global Top Multiple Sclerosis Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Sclerosis Therapeutics as of 2021)
    Figure 19. The Top 10 and 5 Players Market Share by Multiple Sclerosis Therapeutics Revenue in 2021
    Figure 20. North America Multiple Sclerosis Therapeutics Revenue Market Share by Company in 2021
    Figure 21. North America Multiple Sclerosis Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 22. North America Multiple Sclerosis Therapeutics Revenue Market Share by Distribution Channel (2017-2028)
    Figure 23. North America Multiple Sclerosis Therapeutics Revenue Share by Country (2017-2028)
    Figure 24. U.S. Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 25. Canada Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 26. Europe Multiple Sclerosis Therapeutics Revenue Market Share by Company in 2021
    Figure 27. Europe Multiple Sclerosis Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 28. Europe Multiple Sclerosis Therapeutics Revenue Market Share by Distribution Channel (2017-2028)
    Figure 29. Europe Multiple Sclerosis Therapeutics Revenue Share by Country (2017-2028)
    Figure 30. Germany Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 31. France Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 32. U.K. Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 33. Italy Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 34. Russia Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 35. Asia Pacific Multiple Sclerosis Therapeutics Revenue Market Share by Company in 2021
    Figure 36. Asia Pacific Multiple Sclerosis Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 37. Asia Pacific Multiple Sclerosis Therapeutics Revenue Market Share by Distribution Channel (2017-2028)
    Figure 38. Asia Pacific Multiple Sclerosis Therapeutics Revenue Share by Region (2017-2028)
    Figure 39. China Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 40. Japan Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 41. South Korea Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 42. India Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 43. Australia Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 44. Taiwan Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 45. Indonesia Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 46. Thailand Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 47. Malaysia Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 48. Philippines Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 49. Vietnam Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 50. Latin America Multiple Sclerosis Therapeutics Revenue Market Share by Company in 2021
    Figure 51. Latin America Multiple Sclerosis Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 52. Latin America Multiple Sclerosis Therapeutics Revenue Market Share by Distribution Channel (2017-2028)
    Figure 53. Latin America Multiple Sclerosis Therapeutics Revenue Share by Country (2017-2028)
    Figure 54. Mexico Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 55. Brazil Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 56. Argentina Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 57. Middle East and Africa Multiple Sclerosis Therapeutics Revenue Market Share by Company in 2021
    Figure 58. Middle East and Africa Multiple Sclerosis Therapeutics Revenue Market Share by Type (2017-2028)
    Figure 59. Middle East and Africa Multiple Sclerosis Therapeutics Revenue Market Share by Distribution Channel (2017-2028)
    Figure 60. Middle East and Africa Multiple Sclerosis Therapeutics Revenue Share by Country (2017-2028)
    Figure 61. Turkey Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 62. Saudi Arabia Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 63. U.A.E Multiple Sclerosis Therapeutics Revenue (2017-2028) & (US$ Million)
    Figure 64. Novartis Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2017-2022)
    Figure 65. Teva Pharmaceuticals Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2017-2022)
    Figure 66. Sanofi Genzyme Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2017-2022)
    Figure 67. Bayer Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2017-2022)
    Figure 68. Pfizer Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2017-2022)
    Figure 69. Biogen Idec Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2017-2022)
    Figure 70. Merck Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2017-2022)
    Figure 71. AbbVie Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2017-2022)
    Figure 72. Bottom-up and Top-down Approaches for This Report
    Figure 73. Data Triangulation
    Figure 74. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$5600

This license allows only one user to access the PDF.
Electronic (PDF)

$8400

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$11200

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS